New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
06:17 EDTIPSEYIpsen downgraded to Hold from Buy at Jefferies
News For IPSEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
05:17 EDTIPSEYIpsen, Lexicon enter into ex-North America/Japan licensing agreement
Ipsen (IPSEY) and Lexicon Pharmaceuticals (LXRX) announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase, or TPH, that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the FDA, and has received orphan drug designation from the European Medicines Agency. Under the financial terms of the agreement, Lexicon is eligible to receive up to $145M, comprising $23M upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
October 10, 2014
11:33 EDTIPSEYIpsen announces positive Phase III results for Decapeptyl
Ipsen announced positive results from the phase III study of Decapeptyl administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology 14th Central European Meeting in Cracow, Poland. The primary objective of the study was to assess the efficacy and safety profile of the sustained-release Decapeptyl formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer. This objective was met with castration levels of testosterone achieved in 97.6% of men at week 4 and castration maintained in 96.6% of these men at week 26. The efficacy results and safety profile of Decapeptyl administered by the subcutaneous route are consistent with the known efficacy and safety profile of Decapeptyl administered by the intramuscular route. Based on these results, Ipsen has applied for the addition of the subcutaneous route, alongside the intramuscular route, to the label of Decapeptyl.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use